medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2013; 12 (1)


Hepatitis C virus infection in patients with primary biliary cirrhosis

Hsuan-Wei C, Hsin-Hung H, Ching-Huang L, Wei-En C, Yu-Lueng S, Wei-Kuo C, Tsai-Yuan H, Heng-Cheng C

Idioma: Ingles.
Referencias bibliográficas: 33
Paginas: 78-84
Archivo PDF: 98.30 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2006; 353: 1261-73.

  2. Myers RP, Shaheen AA, Fong A, Burak KW, Wan A, Swain MG, Hilsden RJ, et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population- based study. Hepatology 2009; 50: 1884.

  3. Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008; 3: 1.

  4. Poupon RE, Lindor KD, Parés A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-16.

  5. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United- States. Liver Transpl 2003; 9: 331-8.

  6. Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, Mal F, et al. Lymphocytic sialadenitis of Sjögren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339: 321-3.

  7. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995; 22: 364-9.

  8. Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999; 31: 210-6.

  9. Floreani A, Baragiotta A, Leone MG, Baldo V, Naccarato R. Primary biliary cirrhosis and hepatitis C virus infection. Am J Gastroenterol 2003; 98: 2757-62.

  10. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.

  11. Housset C, Hirschauer C, Degos F. False positive anti-HCV in biliary cirrhosis. Lancet 1991; 114: 252 (Letter).

  12. Fusconi M, Lenzi M, Ballardini G, Miniero R, Cassani F, Zauli D, Bianchi FB. Anti-HCV testing in autoimmune hepatitis and primary biliary cirrhosis. Lancet 1990; 336: 823.

  13. Imada J, Hoshino H, Nishimura D, Morita K, Yoshida N, Katada N, Sano H, et al. Case report: multiple cancers: hepatocellular carcinoma and adenocarcinomas of the common bile duct and the gall-bladder in a woman with primary biliary cirrhosis. J Gastroenterol Hepatol 1996; 11: 546-50.

  14. Hoso M, Nakanuma Y, Kawano M, Oda K, Tsuneyama K, van de water J, Gershiwin ME. Granulomatous cholangitis in chronic hepatitis C: a new diagnostic problem in liver pathology. Pathol Int 1996; 46: 301-5.

  15. Mouelhi L, Chaieb M, Sfar I, Debbeche R, Trabelsi S, Gorgi Y, Najjar T. Chronic viral C hepatitis associated with primary biliary cirrhosis. Report of two cases. Rev Med Interne 2009; 30: 537-9.

  16. Ramos-Casals M, Pares A, Jara LJ, Solans R, Viñas O, Vázquez P, Sánchez-Tapias, et al; HISPAMEC Study Group. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J Viral Hepat 2005; 12: 648-54.

  17. Sung JL. Prevention of hepatitis B and C virus infection for prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S370-S376.

  18. Wang JT, Wang TH, Sheu JC, Tsai SJ, Hsieh YS, Lin DT, Wang CY, et al. 1993. Hepatitis C virus infection in volunteer blood donors in Taiwan. Evaluation by hepatitis C antibody assays and the polymerase chain reaction. Arch Pathol Lab Med 1993; 117: 152-6.

  19. Nakamura M, Yasunami M, Kondo H, Horie H, Aiba Y, Komori A, Migita K, et al; PBC Study Group in NHOSLJ. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): The HLA-DRB1 polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC. Hepatol Res 2010; 40: 494- 504.

  20. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview based study of 1032 patients. Hepatology 2005; 42: 1194-202.

  21. Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, Odin JA, et al. Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites. Hepatology 2006; 43: 525-31.

  22. Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med 2011; 50: 1-10.

  23. Cavazza A, Caballería L, Floreani A, Farinati F, Bruguera M, Caroli D, Parés A. Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Comparative Analysis from Two Centers. Hepatology 2009; 50: 1162-8.

  24. Macaron C, Hanouneh IA, Zein NN. Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis. Hepatology 2010; 52: 2239; author reply 2239-40.

  25. Michel F, Toussirot E, Wendling D. Primary biliary cirrhosis and systemic lupus erythematosus. A new case report. Rev Rhum Engl Ed 1998; 65: 504-7.

  26. Shizuma T, Kuroda H. A case of primary biliary cirrhosis which developed eight years after diagnosis of systemic lupus erythematosus. Intern Med 2011; 50: 321-4.

  27. Watt EF, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004; 97: 397-406.

  28. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 26: 975-82.

  29. Yoshikawa M, Mimura M, Shiroi A, Kojima H, Fukui H, Sugimoto Y, Mochi T. Primary biliary cirrhosis exacerbated by a course of acute hepatitis C and subsequent interferon therapy. Am J Gastroenterol 2000; 95: 2396-7.

  30. Maeda T, Onishi S, Miura T, Iwamura S, Tomita A, Saibara T, Yamamoto Y. Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C. Dig Dis Sci 1995; 40: 1226-30.

  31. D’Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F, Consoli G. Primary biliary cirrhosis induced by interferon- alpha therapy for hepatitis C virus infection. Dig Dis Sci 1995; 40: 2113-6.

  32. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.

  33. Chung RT. A Watershed Moment in the Treatment of Hepatitis C. N Engl J Med 2012; 366: 273-5.




2020     |     www.medigraphic.com